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my tube (t-tube) insertion and 27% had abnormal hearing. 
There was no significant difference between the treatment 
groups for annual incidence of OM episodes (untreated con-
trol: 1.9  8 1.4; GH-treated: 1.5  8 1.6, p = 0.17). A quarter of 
the subjects underwent ear surgeries (mainly t-tube inser-
tions) during the study. Recurrent or persistent abnormality 
of ME function on tympanometry was present in 28–45% of 
the girls without t-tubes at the 6 postbaseline visits. Hearing 
deficits were found in 19–32% of the girls at the annual post-
baseline visits. Most of these were conductive deficits, how-
ever, 2 girls had findings consistent with sensorineural hear-
ing loss, which was evident before 3 years of age.  Conclu-
sions: Ear and hearing problems are common in infants and 
toddlers with TS and are not significantly influenced by GH 
treatment. Girls with TS need early, regular and thorough ME 
monitoring by their primary care provider and/or otolaryn-
gologist, and at least annual hearing evaluations by a pedi-
atric audiologist.  Copyright © 2010 S. Karger AG, Basel 
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 Abstract 
 Context: No randomized, controlled, prospective study has 
evaluated the effect of growth hormone (GH) on the rates of 
middle ear (ME) disease and hearing loss in girls with Turner 
syndrome (TS).  Design: A 2-year, prospective, randomized, 
controlled, open-label, multicenter, clinical trial (‘Toddler 
Turner Study’; August 1999 to August 2003) was carried out. 
 Setting: The study was conducted at 11 US pediatric endo-
crine centers.  Subjects: Eighty-eight girls with TS, aged 9 
months to 4 years, were enrolled.  Intervention: The inter-
ventions comprised recombinant GH (50   g/kg/day, n = 45) 
or no treatment (n = 43) for 2 years.  Main Outcome Mea-
sures: The outcome measures included occurrence rates of 
ear-related problems, otitis media (OM) and associated anti-
biotic treatments, tympanometric assessment of ME func-
tion and hearing assessment by audiology.  Results: At base-
line, 57% of the girls (mean age = 1.98  8 1.00 years) had a 
history of recurrent OM, 33% had undergone tympanosto-
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 Introduction 
 Turner syndrome (TS), one of the most common hu-
man genetic disorders, occurs in approximately 1: 2,000 
live female births  [1] . Affected phenotypic females have a 
range of problems caused by loss of all or part of the sec-
ond sex chromosome, specifically, its distal short arm, 
including short stature, gonadal failure, hearing loss, car-
diovascular abnormalities and nonverbal learning dis-
abilities  [2] . Of the many chronic health problems faced 
by individuals with TS, ear disease and hearing loss are 
among the most significant and troublesome  [3, 4] . Al-
though a number of cross-sectional, mainly retrospec-
tive, studies have reported an increased prevalence of oti-
tis media (OM) and hearing loss in school-aged girls and 
women with TS [ 5–9 , reviewed in  10 ], no large-scale, pro-
spective study has investigated the prevalence and natu-
ral history of ear disease and hearing loss in infants and 
toddlers. The paucity of data in very young girls is of par-
ticular concern given the susceptibility of children in this 
age group to middle ear (ME) disease and the importance 
of the preschool years for learning and language develop-
ment  [11] .
 Recombinant growth hormone (GH) is commonly 
used to treat short stature in children with TS  [3] and a 
potential influence of GH treatment on ear disease was 
suggested by 2 GH trials in which OM and other ear dis-
orders were reported as adverse events (AEs) with greater 
frequency for the GH-treated than non-GH-treated girls 
 [12, 13] . However, the significance of these findings was 
unclear, as neither study was designed to prospectively 
investigate the effect of GH treatment on ear disease, thus 
the data were gleaned from clinical trial AE reports, ren-
dering them potentially subject to various reporting bi-
ases  [14] . Given the limitations of these studies, further 
data are required to clarify the effect, if any, of GH treat-
ment on ear disease in young girls with TS. We hypoth-
esized that GH therapy would decrease, rather than in-
crease, the prevalence of OM and conductive hearing im-
pairment in girls with TS by improving the growth and 
development of the ME system. Therefore, the aims of 
this study were to prospectively evaluate the effects of 2 
years of GH treatment on the rates of acute OM, abnor-
mal ME function and hearing loss in a large cohort of 
infants and toddlers with TS.
 Materials and Methods 
 Study Design 
 This prospective, randomized, controlled, open-label study 
(Clinical Trial Registry number: NCT00406926), conducted be-
tween August 1999 and August 2003, was approved by the review 
boards of the 11 participating institutions in the USA, and per-
formed in accordance with the ethical principles of the Declara-
tion of Helsinki. The primary aim of the study, on which the sam-
ple size was calculated, was to determine whether early initiation 
of GH treatment in girls with TS aged 9 months to 4 years could 
prevent the growth failure that otherwise occurs  [15] . As a pre-
specified secondary objective, this study sought to determine in 
a prospective fashion whether GH treatment would reduce the 
rates of ME disease and/or hearing loss in this population. How-
ever, it should be noted that the study was not formally powered 
to address these secondary objectives.
 Subjects 
 Subjects were eligible to participate if they: were aged between 
9 months and 4 years; had karyotype-proven TS; had written in-
formed consent from their legal guardian(s) and were excluded if 
they had any Y chromosomal component in the karyotype and 
gonads in situ or were receiving any concurrent treatment that 
might influence growth  [15] .
 Treatment Intervention 
 Using a phone-in, interactive voice response system, the sub-
jects were randomized in a 1: 1 ratio to either a nontreatment 
control group or a GH treatment group. The GH group received 
daily subcutaneous injections of 50   g/kg of recombinant hu-
man GH (somatropin, rDNA origin; Humatrope  , Eli Lilly & 
Co., Indianapolis, Ind., USA); the control group received no in-
jections. A 10-year extension study of this cohort was initiated in 
2005.
 Measures 
 Sociodemographic data were collected at baseline for a num-
ber of variables that could influence susceptibility to ear disease 
( table 1 ), including parental education level (a marker of socioeco-
nomic status)  [16] , number of siblings in the home, average num-
ber of children in the child’s daytime location, daytime environ-
ment (e.g. own home, other home setting, day care facility) and 
the presence of a smoker in the home  [17] . After a detailed baseline 
evaluation, the subjects were followed at approximately 4-month 
intervals for 2 years.
 The outcomes of primary interest for this analysis were the oc-
currence rates of OM, ME dysfunction (defined below) and hear-
ing loss. To obtain detailed information on ear-related events be-
tween the 4-month study visits, the girls’ families were provided 
with diaries specifically designed for the collection of data regard-
ing ear status. The parents were instructed to record all visits to 
health care providers for any ear-related concerns and all antibi-
otic prescriptions for new ear problems. Diary information was 
entered into the case report forms by the study coordinators at 
each visit. In addition, standard AE reports were collected and the 
families were specifically asked at each study visit whether the 
child had experienced any of the following ear, nose and throat 
(ENT)-related events since the previous visit: head trauma with 
loss of consciousness or skull fracture, tympanostomy tube
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45,X 29 (67) 27 (60) 56 (64)
45,X/46,XX 7 (16) 7 (16) 14 (16)
Other 7 (16) 11 (24) 18 (20)
Medical history
Breast fed <3 months 24 (56) 25 (56) 49 (56)
Craniofacial anomaly 3 (7) 9 (20) 12 (14)
Recurrent ear infection 24 (56) 26 (58) 50 (57)
Tympanostomy tubes 13 (30) 16 (36) 29 (33)
Tonsillectomy 2 (5) 1 (2) 3 (3)
Adenoidectomy 2 (5) 1 (2) 3 (3)
Cholesteatoma 1 (2) 0 (0) 1 (1)
Mastoiditis 1 (2) 0 (0) 1 (1)
Exposure to ototoxic druga 3/42 (7) 4/43 (9) 7/85 (8)
Clinical
Tympanostomy tube(s) present 10/41 (24) 12/44 (27) 22/85 (26)
Abnormal ME function by tympanometry
(1 or both ears)b 17/28 (61) 18/27 (67) 35/55 (64)
Abnormal hearing on audiometry (1 or both ears) 8/38 (21) 13/41 (32) 21/79 (27)
Chronological age, years 1.9781.01 1.9881.01 1.9881.00
Height SDS –1.7681.07 –1.4281.00 –1.5981.04
Weight SDS –1.7781.46 –1.3181.18 –1.5481.34
Sociodemographic
Parental education at least high school
Mothers 42 (98) 44 (98) 86 (98)
Fathers 42 (98) 44 (98) 86 (98)
Both parents at home 41 (95) 39 (87) 80 (91)
Siblings at home
0 11 (26) 13 (29) 24 (27)
1 19 (44) 11 (24) 30 (34)
2 8 (19) 15 (33) 23 (26)
3 4 (9) 2 (4) 6 (7)
≥4 1 (2) 4 (9) 5 (6)
Subject’s daytime location
Own home 33 (77) 36 (80) 69 (78)
Other home 6 (14) 4 (9) 10 (11)
Agency 4 (9) 5 (11) 9 (10)
Children in daytime setting
Subject only 9 (21) 17 (38) 26 (30)
2–3 23 (53) 17 (38) 40 (45)
4–7 5 (12) 4 (9) 9 (10)
≥8 6 (14) 7 (16) 13 (15)
Smoker in subject’s home
No 28 (65) 37 (82) 65 (74)
Yes 15 (35) 8 (18) 23 (26)
Values are numbers of cases with percentages (in parentheses) of the number of subjects in each group with 
available data, or means 8 SD. There were no statistically significant differences between the treatment groups. 
SDS = Standard deviation score.
a Data were missing for 3 subjects. 
b Numbers reflect only children without t-tubes, as t-tubes are intrinsically associated with altered tympa-
nometry profiles. 
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(t-tube) insertion, other ear surgery (e.g. myringotomy, t-tube re-
moval), cholesteatoma, mastoiditis, tonsillectomy, adenoidecto-
my or exposure to ototoxic medications (salicylates, nonsteroidal 
anti-inflammatory drugs, aminoglycosides, erythromycin, van-
comycin, capreomycin, metronidazole, loop diuretics). The oc-
currence rate and duration of OM for each subject were deter-
mined by detailed evaluation of the subjects’ diary information 
and AE reports, which were reviewed by 1 of the authors (M.L.D.) 
to determine the events that represented OM (e.g. ‘middle ear in-
fection’, ‘right otitis media’) versus other events (e.g. ‘left ear 
bleeding’, ‘ear pain’).
 Ear examinations using a pneumatic otoscope (model 20200 
3.5V, Welch Allyn Inc., Skaneateles Falls, N.Y., USA) were per-
formed at each visit for the presence or absence of acute OM, tym-
panic membrane perforation(s) and t-tube(s). Because we were 
interested in abnormalities of ME function as well as effusion, as-
sessment at each visit by tympanometry (GSI 38 Auto-Tymp, Gra-
son-Stadler Inc., Milford, N.H., USA) included 2 acoustic immit-
tance measures known to be highly sensitive to abnormalities of 
ME function – peak compensated acoustic admittance and tym-
panometric width  [18] . Acoustic admittance magnitude was mea-
sured in acoustic millimhos over an ear canal pressure range of 
+200 to –400 daPa. Tympanometry results were considered ab-
normal, representing ME dysfunction, under the following con-
ditions: for children  ̂  1 year of age: static admittance  ! 0.2 mmho 
and/or tympanometric width  1 235 daPa; for children  1 1 year old: 
static admittance  ! 0.3 mmho and/or tympanometric width  1 200 
daPa  [19–22] . The t-tubes were considered patent when a flat tym-
panogram was accompanied by an equivalent volume  1 1.0 ml 
 [23] . An individual child was designated as having abnormal ME 
function if tympanometric analysis was abnormal for 1 or both 
ears.
 In addition to the 4-monthly assessments for ME disease, 
hearing was evaluated annually by an audiologist in an acousti-
cally controlled test room using calibrated equipment. A member 
of the research team (J.R.) provided detailed age-specific audiol-
ogy protocols and consulted with the audiologists as needed. In 
general, girls  ! 2.5 years old were assessed using visual reinforce-
ment audiometry (VRA) in sound field, which tests binaural 
hearing sensitivity but cannot differentiate one ear from the oth-
er. The test stimuli comprised warbled pure tones (500, 1,000, 
2,000 and 4,000 Hz) delivered by loudspeaker. Because responses 
to this testing reflect hearing in the better ear, hearing was as-
sumed to be abnormal in both ears if the mean hearing thresholds 
across the test frequencies were  1 25 dB hearing level (HL). Older 
girls ( 6 2.5 years) were assessed using conditioned play audiom-
etry (CPA), which was used to test each ear independently via 
earphones and included a broader range of air-conducted pure-
tone stimuli (250, 500, 1,000, 2,000, 4,000 and 8,000 Hz); hearing 
was considered abnormal in an ear if the mean hearing thresholds 
obtained across the test frequencies were  1 20 dB HL. An indi-
vidual child was designated as having abnormal hearing sensitiv-
ity if her hearing was abnormal on either VRA (ear undeter-
mined) or for one or both ears on CPA. Because of the longitudi-
nal nature of the study and the increasing age and developmental 
level of the girls over its 2-year duration, data from VRA and CPA 
were combined for analysis.
 Insulin-like growth factor-I (IGF-I) was assayed by Esoterix 
Endocrinology (Calabasas Hills, Calif., USA) on blood samples 
obtained at baseline, as well as 4, 12 and 24 months  [15] .
 Statistical Methods 
 The occurrences of OM based on diary information and AE 
reports were summarized for number and duration of OM events 
per subject, per year. To determine age-related patterns of OM, 
the frequency and duration of these events were analyzed for the 
following age groups:  ! 2, 2 to  ! 3, 3 to  ! 4, 4 to  ! 5 and  6 5 years, 
using means weighted by the amount of time spent by each subject 
within the age interval.
 ME function (tympanometry) was summarized for percent of 
subjects at each visit (and across all postbaseline visits) with nor-
mal results, findings consistent with t-tube(s), abnormal findings 
or missing data. The results of annual hearing tests were summa-
rized for percent of subjects with abnormal hearing (see ‘Mea-
sures’), with or without associated ME dysfunction, at baseline, 
and 12 and 24 months.
 Associations were evaluated between sociodemographic char-
acteristics, IGF-I standard deviation score (SDS) and history of 
recurrent OM, number of on-study days of OM, abnormal ME 
function and hearing loss at baseline and endpoint using Pearson 
correlations. Between-group comparisons for continuous vari-
ables (e.g. age, IGF-I SDS) were made using an independent-group 
t test or analysis of variance with baseline age group ( ! 2.5 or  6 2.5 
years) and treatment group as explanatory variables. Unless stat-
ed otherwise, continuous data are reported as means  8 1 stan-
dard deviation (SD). Between-group comparisons for categorical 
variables were made with Fisher exact tests. All tests were 2-sided 
and conducted at the 0.05 level of significance. Statistical analyses 
were performed using the SAS software system (version 8.2, SAS 
Institute, Inc., Cary, N.C., USA).
 Results 
 Of the 88 girls with karyotype-proven TS randomized 
in the study, 87 (control: n = 42; GH: n = 45) had post-
baseline data available and 78 completed the 2-year study. 
The primary efficacy and safety data have been reported 
 [15] .
 Baseline Data 
 At study entry (mean age = 1.98  8 1.00 years), 50/88 
(57%) of the girls already had a history of recurrent OM, 
29/88 (33%) had undergone t-tube insertion and 22/85 
(26%) had t-tube(s) visible by otoscopy ( table 1 ). Given the 
known detrimental effect of cigarette smoke on ME func-
tion, it was notable that 23/88 girls (26%) had a smoker in 
the home. By tympanometric evaluation (categorized as: 
normal, functional t-tube, abnormal or unsuccessful), 
19/87 girls (22%) were normal, 19/87 girls (22%) had ab-
normal ME function characteristic of functional t-tubes, 
35/87 (40%) had other abnormal ME findings and 14/87 
girls (16%) had unsuccessful tests. Furthermore, hearing 
was abnormal for 21/79 (27%) of the girls. Not surpris-
ingly, there were significant positive baseline associations 
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between the presence of t-tube(s) and a history of recur-
rent OM (p = 0.0001) and between the presence of t-
tube(s) and ME dysfunction (p = 0.04). Interestingly, sub-
jects with a baseline history of recurrent OM had a sig-
nificantly lower mean IGF-I SDS than those without such 
history (–0.59  8 0.90, 95% CI = –0.86 to –0.32 versus 
0.05  8 0.76, 95% CI = –0.22 to 0.32, p = 0.0015). How-
ever, this finding was not associated with any significant 
difference in prestudy growth, as baseline weight SDS, 
length SDS and BMI were similar for girls with or without 
a history of recurrent OM (without OM history: length 
SDS = –1.6  8 1.1, weight SDS = –1.9  8 1.3, BMI = 16.23 
 8 1.22; with OM history: length SDS = –1.6  8 1.0, weight 
SDS = –1.3  8 1.3, BMI = 16.46  8 1.41). There was no as-
sociation between any of the ear disease measures and 
karyotype or other baseline characteristics.
 On-Study (Postbaseline) Data 
 Otitis Media. Most girls (87%) had at least 1 episode of 
OM during the 2-year study period. The average annual 
number of OM events per subject was: control: 1.9  8 1.4; 
GH: 1.5  8 1.6 (p = 0.17;  table 2 ). Whereas 55% of the GH-
treated girls had  ̂  1 episode of OM per year, this was true 
for only 26% of the girls in the control group ( fig. 1 ). The 
episodes of OM tended to be quite lengthy (average days: 
control: 15.8  8 16.7; GH: 18.2  8 24.9, p = 0.34). The av-
erage number of days per year with OM was similar for 
the control and GH groups (31.8  8 30.0 vs. 25.7  8 31.7; 
p = 0.36). Based on data from subject diaries, antibiotics 
for new ear-related problems were prescribed approxi-
mately once every 4 months in both groups.
 When evaluated by age group ( ! 2, 2 to  ! 3, 3 to  ! 4, 4 
to  ! 5 and  6 5 years) the average annual number of OM 
events and cumulative days of OM showed declining 
trends, as would be expected with increasing age ( table 2 ). 
However, the number of days with OM was highly vari-
able, ranging from 0 to 146 days per subject per year; 
there were no significant between-group differences for 
age-related rates or durations of OM.
 Ear-Related AEs. As expected in a TS cohort, ear-re-
lated events were common. More than a third of the sub-
jects (32/87; 17 control, 15 GH) underwent  6 1 ear surger-
ies (mainly t-tube insertions with occasional t-tube re-
movals and stand-alone myringotomies) during the 
study. In addition, 16/87 girls (18%) (control: 7; GH: 9) 
underwent tonsillectomy and/or adenoidectomy. There 
were few case reports for any of the other prespecified 
events and no significant between-group differences on a 
by-visit or cumulative basis.
 ME Function (Tympanometry).  ME dysfunction was 
common in this young cohort, being present in 28–45% 
of the subjects overall at the 6 post-baseline visits (con-
trol: 34  8 5%; GH: 39  8 8%, NS). Whereas t-tube(s) were 
observed by otoscopy in 32–44% of the subjects at the 6 
postbaseline visits, only 19–24% had tympanometric pro-
files consistent with functional t-tubes, suggesting that 
many of the t-tubes had become occluded. The frequency 
of ME dysfunction was not influenced by GH treatment, 






Episodes per year by age group
<2 years 2.8 (1.6) 2.2 (1.4)
2 to <3 years 2.0 (1.6) 1.4 (1.7)
3 to <4 years 1.7 (1.6) 1.2 (1.3)
4 to <5 years 1.4 (1.4) 0.8 (1.0)
≥5 years 1.2 (1.3) 1.3 (2.2)
Average for all agesa 1.9 (1.4) 1.5 (1.6)
Days per year by age group
<2 years 50.9 (43.2) 31.1 (24.0)
2 to <3 years 26.6 (25.3) 28.5 (47.1)
3 to <4 years 25.7 (36.4) 21.3 (26.8)
4 to <5 years 21.7 (39.9) 13.1 (17.5)
≥5 years 8.8 (9.3) 25.7 (29.4)
Average for all agesb 31.8 (30.0) 25.7 (31.7) 
Data are provided as means (SD). * One subject who had no 
post-baseline data was excluded.

















0 1 2 3 4 5 6 7 8 9
Control group, n = 42
GH group, n = 44
 Fig. 1. Frequency distribution of annual number of episodes of 
OM per subject. The distribution is shifted to the left somewhat 
(fewer episodes) for the GH group compared with the control 
group (p = 0.08). 
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as there was no significant difference between the treat-
ment groups at any postbaseline visit ( fig. 2 ). Tympanom-
etry was unsuccessful about a quarter of the time (29  8 
7% of the control girls and 24  8 7% of the GH-treated 
girls across the 6 postbaseline visits) because of the age 
and cooperation levels of the subjects. Therefore, the per-
centages of subjects whose findings were consistent with 
t-tubes or ME dysfunction are likely underestimates.
 Hearing . The proportion of subjects with abnormal 
hearing was high throughout the study and did not differ 
significantly between the groups ( table 3 ). As expected in 
this young population, the hearing deficit appeared to be 
conductive in nature, as suggested by the coexistence of 
ME dysfunction with hearing loss in most affected girls 
( table 3 ). Although the prevalence of hearing loss in-
creased somewhat from baseline to endpoint in the con-
trols (15  ] 21%) and decreased moderately in the GH-
treated subjects (35  ] 17%), the between-group differ-
ences were not significant ( table 3 ).
 Findings consistent with sensorineural hearing loss 
(SNHL; abnormal hearing in the presence of normal ME 
function) were present in 2 subjects at baseline. SNHL 
was subsequently confirmed for 1 participant, whose 
hearing loss was apparent by 16 months of age. One ad-
ditional GH-treated subject had audiometry consistent 
with SNHL at the final study visit at 33 months of age 
( table 3 ).
 Associations between Ear Disease and Historical, So-
ciodemographic and Examination Findings. Associations 
between medical history, sociodemographic variables 
and examination findings, and the presence or absence 
of ear disease, were examined by treatment group at the 
2-year study endpoint. Although there was a baseline as-
sociation between history of recurrent OM and IGF-I 
SDS (described above), there was no correlation between 
on-study days of OM and endpoint IGF-I SDS. No vari-
ables were significantly associated with ME dysfunction 
by tympanometry. However, abnormal hearing at the 
endpoint visit in the control group was significantly re-
lated to the child’s daytime care setting being outside the 
home (p = 0.0032) and to the presence of  1 3 additional 
children in the day care environment (p = 0.0038). These 
associations were not significant for the GH-treated 
group.
 Discussion 
 Although many studies have reported data on otolog-
ic abnormalities in patients with TS  [5–10, 13, 24] , none 
has evaluated ear disease in a large cohort of very young 
GH-treated vs. untreated girls in a prospective, longitu-
dinal fashion. Thus, the age at onset of ear and hearing 
problems in TS, and their natural history, have been 













































 Fig. 2. Percentage of subjects in the control ( a ) and GH ( b ) group at each visit who had evidence of ME dysfunc-
tion by tympanometry (1 or both ears); t-tube(s) in 1 or both ears and total percentage of subjects with abnormal 
tympanometry. There were no significant between-group differences at any study visit for rates of abnormal 
tympanometry or presence of tympanostomy tubes. 
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some of these gaps, demonstrating that significant ME 
dysfunction, as evidenced by tympanometric abnormali-
ties, was common in these preschool children. Further-
more, by the average age of 2 years (at study entry) ap-
proximately 60% of the girls with TS had a history of re-
current OM, compared with the prevalence of 10–20% in 
infants and preschool children without TS  [17, 19] . Dur-
ing the 2-year study, the participants had OM for a cumu-
lative period of about 1 full month per year. The associ-
ated morbidity was significant, as episodes were often
accompanied by pain, perforation, drainage and/or bleed-
ing; doctor visits were frequent and  6 1 antibiotics were 
usually prescribed for each recorded episode. As recur-
rent OM predisposes to chronic OM with effusion, it rep-
resents a precursor of ME dysfunction and conductive 
hearing loss (CHL)  [5, 9, 10] . Indeed, consistent with the 
high rates of OM, t-tube insertion and ME dysfunction 
were common in our cohort. Furthermore, as a conse-
quence of ME dysfunction, CHL secondary to OM was 
also frequent, being present in 20–30% of these  ! 6-year-
old girls at each of the annual timepoints. One potential 
limitation of our study was that for logistic reasons, ENT 
examinations were not performed by otolaryngologists 
but by the pediatric endocrinologists who participated as 
principal investigators at the 11 study sites. While we rec-
ognize that optimal care for girls with TS should include 
regular careful assessment by otolaryngologists, we nev-
ertheless believe our results to be reliable, based on the 
breadth of measures used to assess ME function and 
hearing in our study.
 The increased prevalences of OM and hearing loss in 
TS appear to result from growth abnormalities of the ME 
system  [25] , which includes the eustachian tube and its 
surrounding structures – the nose, nasopharynx and pal-
ate at its proximal end, and the ME and mastoid cells at 
its distal end. In the typical infant and young child the 
eustachian tube is shorter overall, has a relatively shorter 
and narrower osseous portion, less tubal mass and stiff-
ness than in adulthood and lies at a 10-degree angle rela-
tive to the horizontal plane. Vertical development of the 
skull increases the angle of the skull base, allowing the 
eustachian tube to reach its mature angle of approximate-
ly 45° in mid-childhood  [26] . It has been hypothesized 
that the short, flattened cranial base with small poorly 
Table 3. Hearing and ME function at baseline and at the final study visit











Normal hearing 29 (85) 24 (65) 53 (75) 22 (79) 25 (83)
    With normal ME function 12 (35) 6 (16) 18 (24) 8 (29) 8 (27)
    With patent t-tubesa 7 (21) 6 (16) 13 (18) 6 (21)b 4 (13)b
    With abnormal tympanometryc 10 (29) 12 (32) 22 (31) 8 (29) 13 (43)
Bilateral hearing lossd 5 (15) 13 (35) 18 (25) 6 (21) 5 (17)
    With normal ME function 0 (0) 2 (5) 2 (3 ) 0 (0) 1 (3)
    With patent t-tubesa 0 (0) 4 (11)b 4 (6)b 2 (7) 2 (7)
    With abnormal tympanometryc 5 (15) 7 (19) 12 (23) 4 (21) 2 (13)
Figures are numbers of cases with percentages (in parentheses) 
of subjects with results available in each group. Subjects were in-
cluded in this analysis only if they had both tympanometry and 
audiometry results available at the same visit. There was no sig-
nificant difference between treatment groups for the prevalence 
of hearing deficit at any study visit.
a t-tubes were considered patent when a flat tympanogram was 
accompanied by an equivalent volume >1.0 ml in a subject with 
t-tube visible on otoscopy.
 b One subject in each group also had a tympanic membrane 
perforation on otoscopy. 
c Tympanometry was considered abnormal for subjects <1 year 
of age if static admittance was <0.2 mmho and/or tympanometric 
width >235 daPa. For subjects ≥1 year of age, ME function was 
considered abnormal if static admittance was <0.3 mmho and/or 
tympanometric width >200 daPa. 
d Hearing was considered abnormal if the mean hearing levels 
were >25 dB HL by VRA or >20 dB HL by CPA. Results are pro-
vided for bilateral hearing loss because assessment by VRA per-
formed in sound field reflects the sensitivity of the better ear and 
this will not detect unilateral hearing loss. In addition to the num-
bers for bilateral hearing loss shown in the table, unilateral hear-
ing loss (determined by CPA) was present for 2 girls at baseline 
and 7 girls at the last available assessment.
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pneumatized mastoids in TS results in a relatively short-
er, more horizontal eustachian tube, permitting naso-
pharyngeal reflux and interfering with ME drainage  [17, 
27] . These growth disturbances in TS may result from 
reduced expression of the X(Y)-chromosomal short-stat-
ure homeobox-containing (SHOX) gene  [28] . Lacking all 
or part of the short arm of the second sex chromosome, 
individuals with TS are haploinsufficient for  SHOX . 
 SHOX is highly expressed during normal embryogenesis 
in the first and second pharyngeal arches  [29] (the pre-
cursors to the maxilla and mandible, the ossicles and 
muscles of the ME and the tensor veli palatini, a key mus-
cle in eustachian tube dilation  [30] ). Abnormalities of 
these structures (e.g. palatal dysfunction) as well as lym-
phatic hypoplasia also might contribute to the increased 
rates of OM in TS.
 In addition to high rates of CHL, a high prevalence of 
SNHL has been reported in older girls and women with 
TS  [7, 8, 10, 24, 31, 32] . The prevalence of SNHL increases 
with age; almost 50% of the patients in a Canadian study 
had evidence of SNHL by 21 years of age  [33]  and  1 1 in 4 
women with TS require hearing aids  [32] . The finding in 
the present study of probable early-onset SNHL in 2 girls 
 ! 3 years of age indicates that SNHL may begin very ear-
ly in some patients, confirming a previous case report of 
SNHL in a 4-year-old girl  [34] . While it has been pro-
posed that the propensity for SNHL in TS may be a con-
sequence of abnormal cochlear development as a result of 
prolonged cell cycle time associated with chromosomal 
aneuploidy  [27] , a study of fetal cochlear development re-
vealed no consistent abnormalities in fetuses with TS up 
to 23 weeks’ gestation  [35] . The combination of the high 
rates of CHL resulting from ME disease in childhood and 
progressive SNHL that may begin early in life places pa-
tients with TS at high risk for significant hearing deficits 
throughout life.
As well as carefully assessing the ear and hearing sta-
tus of a very young group of children with TS, this study 
sought to evaluate the effect, if any, of 2 years of GH treat-
ment, initiated between 9 months and 4 years of age, on 
ear disease. This was an important aim because although 
GH treatment for the short stature associated with TS has 
been approved in the USA for  1 13 years, information re-
garding the effects of GH on ear disease in TS is limited. 
Two previous randomized studies in school-aged girls 
had reported higher rates of OM and related ear prob lems 
for GH-treated subjects than for control subjects  [12, 13] . 
In contrast, we hypothesized that GH therapy would de-
crease the propensity for ear disease by stimulating 
growth and development of the cranial base and ME sys-
tem. Consistent with this hypothesis, a study of 2- to 8-
year-old children born small for gestational age found a 
significant age-dependent effect of GH on growth of the 
posterior cranial base  [36] .
 Although the present 2-year study did not demon-
strate a beneficial effect of GH on ear disease in infants 
and toddlers with TS, there was no evidence of a detri-
mental effect. The rates of acute OM, ME dysfunction, 
hearing loss and other ear-related problems in GH-treat-
ed girls in this study were generally similar to, or some-
what lower than, those in non-GH-treated girls. Despite 
the trend toward lower frequency of ear problems in the 
GH-treated group, the study was not powered specifical-
ly to address the between-group differences in ear disease 
and may have been underpowered to detect a beneficial 
GH effect. The findings in the present investigation con-
trast with those of the earlier studies in school-aged girls 
 [12, 13] in which ear problems were more common in 
GH-treated than untreated girls. These differences are 
likely due primarily to the detailed prospective data col-
lection employed in the present study versus standard AE 
reporting in the earlier research. The variation in age of 
the populations studied may also play a role, given the 
higher baseline prevalence of ear disease in younger girls. 
Furthermore, our findings are supported by data from a 
randomized, controlled GH trial in patients with  SHOX 
deficiency in which the rates of ear disease were similar 
in the control and GH-treated groups  [37] .
 Our data have clinical implications for the manage-
ment of young girls with TS. For otherwise healthy chil-
dren, a history of OM and transient CHL does not appear 
to adversely affect development; however, these findings 
cannot be generalized to children at increased risk for 
developmental delays  [38, 39] . Considering the higher 
prevalence of nonverbal learning disabilities in girls with 
TS and their greater reliance on verbal learning and 
speech  [40] , every effort must be made to eliminate or re-
duce avoidable risk factors for hearing loss such as OM, 
exposures to cigarette smoke, ototoxic agents or poten-
tially damaging noise levels  [11] . Given the need for care-
ful monitoring of hearing and ME function, and the lim-
itations of screening tests for the detection of mild, early-
onset cochlear dysfunction  [34] , all girls with TS should 
be evaluated for ear disease by their primary care pro-
vider and a pediatric audiologist on at least an annual 
basis, beginning as soon as possible after diagnosis of 
TS.
 In summary, the data reported here highlight the very 
early onset of significant ear disease, including hearing 
loss, in infants and toddlers with TS. Furthermore, this 
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study provides the first prospectively collected evidence 
that GH treatment does not increase the occurrence of 
ear problems in young girls with TS. Because ear disease 
has a profound impact on the quality of life in this popu-
lation, proactive surveillance and aggressive treatment, 
irrespective of whether or not the child is receiving GH, 
is essential.
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